NVC Eye Care - B (06622.HK): The National Medical Products Administration has accepted the new drug market application for NVK002 (0.02% atropine sulfate eye drops) for the treatment of deepening myopia in children.

Sina Finance News, Ocumension Therapeutics (06622.HK) announced that the China National Medical Products Administration recently accepted the new drug marketing application for NVK002 (0.02% atropine sulfate eye drops), one of the company's core products used to treat progressive myopia in children. The new drug application is classified as a Class II innovative drug.